Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis

Trial Profile

Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Tofacitinib (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ORAL-Start
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Jun 2018 Results comparing pain and HAQ-DI from RA-BEGIN, PREMIER, ORAL-START, AMBITION and FUNCTION studies were presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 15 Nov 2017 Results of pooled post-hoc analysis from six phase III studies including this study, were published in The Journal of Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top